# Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

> **NCT01462942** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2443 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Aclidinium Bromide/Formoterol Fumarate
- **DRUG:** Aclidinium Bromide/Formoterol Fumarate
- **DRUG:** Aclidinium Bromide
- **DRUG:** Placebo
- **DRUG:** Formoterol Fumarate

## Key facts

- **NCT ID:** NCT01462942
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 2443 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462942, "Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01462942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*